Arcadia Biosciences (NASDAQ: RKDA) reported quarterly losses of $(2.10) per share which beat the analyst consensus estimate of $(2.58) by 18.6 percent. This is a 66.72 percent increase over losses of $(6.31) per share from the same period last year. The company reported quarterly sales of $1.17 million which missed the analyst consensus estimate of $1.75 million by 33.14 percent. This is a 17.00 percent increase over sales of $1.00 million the same period last year.